Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Insulet (PODD) Shares Skyrocket, What You Need To Know
Insulet (PODD) Shares Skyrocket, What You Need To Know
Insulet (PODD) Shares Skyrocket, What You Need To Know
Jabin Bastian
Thu, February 19, 2026 at 2:26 AM GMT+9 2 min read
In this article:
PODD
+5.61%
What Happened?
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 5.6% in the afternoon session after the company posted strong fourth-quarter 2025 financial results that beat Wall Street’s expectations.
The company reported fourth-quarter revenue of $783.8 million, up 31.2% from the previous year and surpassing analyst estimates. This growth was driven by strong demand for its Omnipod insulin management systems. Insulet’s profitability also impressed, with adjusted earnings of $1.55 per share, which was 6% above consensus projections. Looking ahead, the company provided a positive outlook, guiding for a 26% year-over-year sales increase for the first quarter of 2026, which was roughly in line with what analysts were expecting.
Is now the time to buy Insulet? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Insulet’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock gained 20.7% on the news that the company reported strong first quarter 2025 results which significantly beat analysts’ constant currency revenue, EPS, and EBITDA expectations. Its quarterly revenue guidance also outperformed Wall Street’s estimates. The key number was a 30% jump in constant currency sales, led by strong growth in the U.S. and a big push overseas, where Omnipod sales rose 36%. Zooming out, we think this was a solid print.
Insulet is down 7.9% since the beginning of the year, and at $260.57 per share, it is trading 26.1% below its 52-week high of $352.82 from September 2025. Investors who bought $1,000 worth of Insulet’s shares 5 years ago would now be looking at an investment worth $953.37.
The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free.
Terms and Privacy Policy
Privacy Dashboard
More Info